Department of Systems and Computational Biology, Albert Einstein College of Medicine, The Bronx, NY, USA.
Department of Systems and Computational Biology, Albert Einstein College of Medicine, The Bronx, NY, USA; Department of Microbiology and Immunology, Albert Einstein College of Medicine, The Bronx, NY, USA.
Trends Pharmacol Sci. 2019 Jul;40(7):495-505. doi: 10.1016/j.tips.2019.04.014. Epub 2019 Jun 3.
Our bodies each possess a unique and dynamic collection of microbes and viruses, collectively the 'microbiome', with distinct metabolic capacities from our human cells. Unforeseen modification of drugs by the microbiome can drastically alter their clinical effectiveness, with the most dramatic cases leading to fatal drug interactions. Pharmaceuticals can be activated, deactivated, toxified, or release metabolites that alter the 'canonical' pharmacokinetics of the drug. Thus, predicting and characterizing microbe-drug interactions is necessary to develop and implement personalized drug administration protocols and, more broadly, to improve drug safety and efficacy. In this review, we focus on microbiome-driven alterations to drug pharmacokinetics and provide a research framework for pharmacologists interested in characterizing microbiome interactions with any drug of interest.
我们的身体各自拥有独特而动态的微生物和病毒集合，统称为“微生物组”，它们具有不同于人类细胞的代谢能力。微生物组对药物的不可预见的修饰会极大地改变它们的临床效果，最严重的情况会导致致命的药物相互作用。药物可以被激活、失活、中毒化，或者释放改变药物“典型”药代动力学的代谢物。因此，预测和描述微生物-药物相互作用对于开发和实施个性化药物管理方案是必要的，更广泛地说，对于提高药物安全性和疗效也是必要的。在这篇综述中，我们重点关注微生物组驱动的药物药代动力学改变，并为对描述任何感兴趣药物的微生物组相互作用感兴趣的药理学家提供研究框架。
